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Abstract
Background: Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their
use is extending to other malignancies. However, we are still learning about immune side effects produced by
these drugs and their severity especially in patients with history of inflammatory diseases.
Case presentation: We present two cases of metastatic melanoma treated with nivolumab and pembrolizumab
(anti PD-1). Both patients developed acute interstitial nephritis during immune checkpoint therapy. We emphasize
the causal association between immune checkpoint inhibitors and the nephritis. The timing of drug administration
and appearance of nephritis is suggestive of a causal relation between the checkpoint inhibitor therapy and this
adverse event.
Conclusions: Although uncommon, some side effects from checkpoint inhibitors can be severe and may need to
be addressed with immunosuppression. Given the increasing frequency of immunotherapy use, awareness should
be raised in regards to immune side effects and their appropriate management.
Keywords: Immune checkpoint inhibitor, Programed death 1 receptor (PD-1), PD-1 ligand (PD-L1), Interstitial
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Background
Programed death 1 receptor (PD-1), transmits inhibitory
signals to immune cells leading to decreased proliferation
and apoptosis. Cancer cells express PD-L1, the ligand of
PD-1, allowing the tumor to escape attack by effector T
cells. Immune checkpoint inhibitors encompass blocking
antibodies to the PD-1/ PD-L1 and CTLA-4 checkpoint
molecules. These drugs block the PD-1/PD-L1 interaction
enhancing the cellular response against the tumor.
Pembrolizumab, an anti-PD-1 antibody, has shown su-
perior progression-free survival (PFS) versus chemother-
apy at 6 months: 34–38% versus 16% PFS, respectively
[1]. Nivolumab, another anti-PD-1 antibody, approved
by the FDA in 2014 to treat metastatic melanoma. A trial
comparing nivolumab to dacarbazine in previously un-
treated patients showed a 12-month survival rate of 73%
versus 42% respectively [2]. Another study compared
nivolumab to dacarbazine or carboplatin/paclitaxel in pa-
tients who progressed on ipilimumab plus or minus
BRAF-inhibitor; results showed response rates of 31.7%
versus 10.6% respectively [3].
Nivolumab, alone or in combination with ipilimumab,
and pembrolizumab as a single agent are indicated to
treat metastatic melanoma [4]. Anti-PD-1 antibodies are
now standard treatment for metastatic or unresectable
melanoma regardless of BRAF V600 mutation status and
are also indicated in non-small cell lung cancer and
renal cell carcinoma. Drug-related adverse events are
mostly Grades 1 and 2; Grade 3 or 4 toxicity occurred in
only 11.7% of patients treated with nivolumab and 17.6%
of those treated with dacarbazine [2].
For nivolumab, serious side effects include colitis,
hepatitis, hypophysitis, adrenal insufficiency, type 1 dia-
betes mellitus, nephritis, extensive rash and encephalitis
[5]. Side effects of pembrolizumab include pneumonitis,
colitis, endocrinopathies, nephritis and transaminases
and bilirubin elevation [6].
Anti PD-1 and anti CTLA-4 combined therapy clinical
trials also noted the occurrence of renal adverse events. For
instance, the CheckMate-069 trial combined Ipilimumab
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3 mg/kg (anti CTLA-4) with Nivolumab 1 mg/kg and
reported a proportion of 1:1000 cases of renal failure
of grade 1-2 while Ipilimumab 3 mg/kg or Nivolumab
3 mg/kg alone reported 0:1000 and 2:1000 cases of
renal failure respectively [7].
Here, we present two patients with advanced melanoma
that developed interstitial nephritis during treatment with
anti-PD1 antibodies.
Cases presentation
Patient 1: A 64-year-old Caucasian male with a history
of metastatic melanoma and prostate cancer in remis-
sion. Melanoma was diagnosed on the left forearm in
December 2008; it was stage IB, Breslow depth 1.2 mm,
non-ulcerated, 2 mitoses/mm2. He was treated with a
wide local excision and sentinel lymph node biopsy was
negative for metastasis. He was followed until February
2010 and subsequently lost to follow up. In June 2015,
he was referred back by a thoracic surgeon who biopsied
two tracheal pigmented metastatic lesions. Evaluation
with PET/CT demonstrated metastasis involving sub-
cutaneous tissue, lymph nodes, right adrenal and the tra-
chea. MRI showed no brain involvement. In September
2015, pembrolizumab was started at 2 mg/kg every 3
weeks; by December 2015, he had completed 5 cycles
with resolution of all lesions except for the right adrenal
as evidenced by PET/CT. Complete biochemical profile
was obtained before each cycle.
At the time of his sixth scheduled cycle he presented
with a serum creatinine of 4.3 mg/dl (baseline Cr: 0.9–
1 mg/dl) and was admitted to the hospital. He had no
history of kidney disease, hypertension, diabetes, gout, kid-
ney stones or frequent UTIs. His outpatient medications
were: fentanyl patch, hydromorphone, hydrocodone-
acetaminophen, lorazepam, omeprazole, temazepam and
montelukast. He also reported occasional use of NSAIDs.
He denied recent upper respiratory symptoms, hematuria,
dysuria, foamy urine, abdominal pain, nausea, vomiting,
diarrhea, GI bleed, mouth ulcers or inflammatory joint dis-
ease. Inflammatory markers and rheumatologic workup
were performed (Table 1). He underwent a kidney biopsy
and was started on IV methylprednisolone 1 g/day for three
days followed by oral prednisone 60 mg/day. Renal biopsy
(Fig. 1) demonstrated diffuse active tubulointerstitial neph-
ritis with severe acute tubular cell injury. Light microscopy
showed mononuclear interstitial inflammation with plasma
cells and eosinophils. Immunohistochemistry revealed an
inflammatory infiltrate composed of CD4 and CD8 T-cells
and macrophages (Fig. 2).
Here was no hypercellularity, necrosis, crescents or inter-
stitial fibrosis. Moderate arteriosclerosis. Immunofluores-
cence showed only trace C3 staining in mesangium and
electron microscopy revealed mild segmental podocyte foot
process effacement 30%. No electron dense deposits or
endothelial tubuloreticular inclusions were seen. Creatinine
was 2.45 mg/dl at discharge and steroids were tapered over
6 weeks. Upon discontinuation of steroids the renal func-
tion returned to baseline. He was not restarted on pembro-
lizumab. However, ipilimumab was started in July 2016 due
to disease progression.
Patient 2: A 78-years-old Hispanic female with history
of acral melanoma, hypertension, psoriasis and arthritis
was admitted with worsening renal function after three
cycles of nivolumab. In September 2013, acral melanoma
was diagnosed in the left fourth toe; Breslow depth was
15 mm, non-ulcerated. PET/CT scan suggested metasta-
ses to left groin lymph nodes. In November 2013, she
underwent amputation of the second and third left toes
with negative margins; sentinel node biopsy was positive
for 3/3 nodes. In December 2013, completion lymphade-
nectomy resulted in 1/4 positive nodes for a total of 4/7
positive lymph nodes. She declined adjuvant therapy and
underwent active surveillance. In May 2015, the patient
presented with a new subcutaneous nodule on the anter-
ior left leg (Fig. 2), which was confirmed as metastatic
melanoma. PET/CT scan revealed multiple in-transit
lesions along the left lower extremity. In July 2015, nivo-
lumab was started at 3 mg/kg. Her baseline serum cre-
atinine was 0.75 mg/dl. After three cycles, nivolumab
was discontinued because of Grade 3 cutaneous toxicity.
Subsequently, a steady increase in the serum creatinine
level was noted. The level in October was 0.92, reaching
3.14 by December 2015 when she was admitted to the hos-
pital. Her medications at the time of admission included:
clonidine, atorvastatin, lorazepam, ferrous sulfate, nifedi-
pine, omeprazole, hydrocodone-acetaminophen, butalbital-
acetaminophen-caffeine; she denied taking NSAIDs or
nephrotoxic medications and her hypertension was con-
trolled. She had no history of diabetes or family kidney
disease. Complete workup for renal and rheumatologic
disease was done similarly to the previous case (Table 1).
She underwent renal biopsy and was started on IV methyl-
prednisolone 1 g/day for 3 days followed by oral prednisone
60 mg daily. Renal biopsy revealed diffuse active on chronic
tubulointerstitial nephritis with acute tubular cell injury.
Light microscopy showed a mononuclear interstitial inflam-
mation with lymphocytes, plasma cells and eosinophils and
no hypercellularity, necrosis or crescents. There was mild
interstitial fibrosis with mild tubular atrophy and mild
arteriosclerosis. Immunofluorescence revealed no glomeru-
lar, tubular or vascular wall immune staining (Fig. 1).
Immunohistochemistry revealed an inflammatory infiltrate
composed of CD4 and CD8 T-cells and macrophages
(Fig. 2). Electron microscopy demonstrated minimal
podocyte foot process effacement and no electron dense
deposits. Discharge renal function was improved (Cr:
1.53 mg/dl) and steroids were tapered down and stopped
after 6 weeks when serum creatinine had normalized
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(Cr: 1.0 mg/dl). She was not restarted on nivolumab
and by June 2016 she had completed three cycles of
temozolomide.
Discussion
As the use of immunotherapy in the treatment of melan-
oma and other malignancies increases, infrequent but
serious adverse events will become more prevalent. In
these two cases treated with anti-PD-1 antibodies, one
patient received pembrolizumab and the other received
nivolumab. Manufacturer information warns of renal
function compromise in 5% of patients treated with
nivolumab (40/787 patients pooled from clinical trials),
of which 0.8% (6/787 cases) presented with Grade 2 and
Grade 3 toxicity. All cases had complete resolution of
the adverse event. Three of them permanently stopped
nivolumab [5]. In the case of pembrolizumab, manufac-
turer data reported nephritis in 0.4% of patients (7/1567
patients pooled from clinical trials), and these included
Grades 2, 3 and 4 nephritis. Two patients (0.1%) per-
manently discontinued pembrolizumab and four out of
seven patients had resolution of nephritis [6].
In our case report, both patients were routinely followed
in the clinic with laboratory tests prior administering
immunotherapy and the rise in creatinine prompted
further workup for kidney pathology. The differential
diagnosis for an insidious rise in creatinine in patients
with no previous history of kidney disease includes prere-
nal (hypovolemia, rhabdomyolysis), renal (rheumatologic
entities, post infectious glomerulopathies, nephrotoxic
medication) and postrenal (urinary system obstruction)
etiologies, for which complete work up was negative. In
the first patient, the timing of the rise in creatinine
levels and the introduction of pembrolizumab in the
absence of any other precipitating factor (other new
drugs, infection) with lack of constitutional symptoms,
pointed to immunotherapy being the most likely cause.
In the second patient, the largest increase in creatinine









ANA titer <40 <40 Negative
CRP 97 37.9 0–3.0
ESR 123 50 0–30
ASO 47 32 <200




ANA screen - serum Negative Positive Negative
Kappa Light Chains Free
light chains
65.26 30.59 3.3–19.4
Lambda light chain, free 29.59 19.03 5.7–26.3
Kappa/ Lambda free 2.45 0.26–1.65 1.61
Hepatitis profile – Acute
panel
Negative Negative Negative
HAV IgM, HCV Ab, ABB
Core IGM, HBV Surface AG
RPR Non-reactive Non-reactive Non-reactive
SM/RNP Antibodies <0.1 <0.1 <0.1
SM Antibodies <0.1 <0.1 <0.1
CPK 38 35 26–192
C3 149 150 90–180
C4 39.8 46.5 10.0–40.0
Uric Acid 6.5 9.5 2.6–6
Vitamin D 25 13.6 32.6 30–100
PTH intact 105.6 79.2 11.1–79.5
Calcium 8.9 8.9 8.5–10.1
Protein electrophoresis with immunofixation
Protein total 7.8 6.8 6.4–8.2 g/dl
Albumin 3.72 4.53 3.57–5.42 g/gl
Alpha 1 0.66 0.46 0.19–0.4 g/dl
Alpha 2 1.44 1.11 0.45–0.97 g/dl
Beta 1 0.47 0.44 0.3–0.59 g/dl
Beta 2 0.56 0.46 0.21–0.53 g/dl
Gamma 0.94 0.79 0.71–1.54 g/dl
Urinalysis




Glucose Negative Negative Negative
Bilirubin Negative Negative Negative
Ketones Negative Negative Negative
pH 6.0 6.5 4.5–8
Protein Negative Negative Negative
Specific gravity 1.005 1.01 Up to 1.035
Table 1 Diagnostic tests in acute renal insufficiency after
checkpoint inhibitors (Continued)
Blood Small Negative Negative
Urobilinogen Negative 0.2 Negative
Nitrites Negative Negative Negative
Leukocyte esterase Large Negative Negative
WBC, UA 38 Negative Negative
RBC, UA 3 Negative Negative
UBAC +1 Negative Negative
Budding Yeast Present Negative Negative
White blood cell clump Present Negative Negative
Data in boldface represent abnormal results
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Fig. 1 a- b patient 1. c-d patient 2. a and c H&E 20x. Tubulointerstitial inflammation with eosinophils and acute tubular epithelial cell injury.
b and c DIF 20x. IgG reactive interstitial plasma cells with tubulointerstitial inflammation
a
b
Fig. 2 Immunohistochemistry of renal biopsies from patients 2 (top panel: a) and 1 (bottom panel: b) reveals an inflammatory infiltrate composed
of CD4 and CD8 T-cells and macrophages.
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occurred after nivolumab had been discontinued; neverthe-
less, the median time for occurrence of renal adverse events
with nivolumab has been reported to be 15.1 weeks and 85%
of these cases occurred within 16 weeks of treatment [8].
Regarding concomitant medications, our first patient
had been using PPI/NSAIDs for many years. However,
AKI only occurred at the time of introducing immuno-
therapy. The second patient had been using PPI for many
years before and after the introduction of nivolumab. It is
unlikely that PPI is the cause of autoimmune nephritis un-
less immunotherapy played a role by adjusting immune
response to PPIs.
Results from both renal biopsies were quite similar. Im-
mune complex deposition diseases were ruled out by hist-
ology; absence of necrosis and granuloma formation ruled
out ischemia and mycobacterial infection respectively and
no infectious collections were seen. Absence of crescents
allayed the concern for lupus nephritis, post infectious or
membranoproliferative glomerulonephritis, IgA nephrop-
athy, etc. Remarkably, the biopsies presented interstitial
infiltration with lymphocytes, plasma cells and eosinophils
which are the most likely culprits of the nephritis.
The reported CD4+/CD8+ T lymphocyte infiltrate in the
setting of treatment with immunotherapy raises the
hypothesis of whether the effector T cells were involved in
provoking kidney injury. PD1 checkpoint inhibition stimu-
lates the T cell effector response, consistent with the infil-
tration of immune cells in the renal parenchyma [9].
Our second patient presented with low titer positive
ANA. This is perhaps reflective of autoimmunity in the
setting of immunotherapy or simply an incidental finding,
not uncommon in the elderly.
Conclusion
Checkpoint inhibitor immunotherapy is highly effective in
treating melanoma and other malignancies. Serious im-
mune adverse events are uncommon, but their numbers
will increase as usage of these drugs becomes more preva-
lent. While renal compromise has been previously docu-
mented, it is warranted to recognize that interstitial
nephritis may present with negative serological, urine and
urine microscopy tests and that it may be only be fully iden-
tified with a kidney biopsy as in the cases we report here.
Close monitoring and a high degree of clinical suspicion is
recommended in patients treated with immune checkpoint
inhibitors and discontinuation of the drug is suggested de-
pending on the severity of the adverse event. For most
grade 1 and 2 toxicities, drug can be safely but carefully
restarted. Patient re-treatment with immunotherapy after
grade 3 toxicity requires close evaluation of the risks. Pa-
tients with grade 4 toxicity should not be re-challenged.
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